Strides Pharma Scien

Strides Pharma Science said on June 27, 2026, that a consortium led by Ascent Capital, along with co‑investor Vintage Classic, will invest in its wholly owned subsidiary Pivot Path Private Limited, a carve‑out from Strides' Global Capability Centre. The transaction values Pivot Path at approximately £2,300 million on a post‑money basis. Strides will realise around £1,000 million while retaining a roughly 20% ownership stake, and the deal includes a primary capital infusion of £500 million to fuel Pivot Path's independent growth. Pivot Path, which was formally separated via an NCLT‑approved Scheme of Arrangement in May 2026, generated revenue of £1,447 million and EBITDA of £169 million in FY26. It offers life sciences consulting, digital transformation, quality and compliance, and AI‑enabled operational services to pharmaceutical clients. Strides' board approved the transaction at a meeting that concluded at 15:50 IST.

Powered by Tijori

May 18 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE MARCH-QUARTER CONSOL NET PROFIT 1.27 BILLION RUPEES

• STRIDES PHARMA SCIENCE MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 13.23 BILLION RUPEES

• STRIDES PHARMA SCIENCE LTD - RECOMMENDS FINAL DIVIDEND OF 5 RUPEES PER SHARE FOR FY2026

Source text: ID:nnAZN4SWWQY

Further company coverage: SRID.NS

(([email protected];))

March 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - ENTERS AGREEMENT TO BUY AND IN-LICENSE GENERIC BRANDS FROM SANDOZ IN AFRICA

• STRIDES PHARMA SCIENCE LTD - INITIAL CONSIDERATION FOR TRANSACTION IS US$ 12 MILLION

• STRIDES PHARMA SCIENCE LTD - DEAL EXPECTED TO CLOSE BY END OF Q2 FY27 PENDING REGULATORY APPROVALS

Source text: ID:nBSE8gPcSB

Further company coverage: SRID.NS

(([email protected];))

Feb 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT GETS USFDA EIR REPORT FOR FORMULATIONS FACILITY AT CHESTNUT RIDGE

Further company coverage: SRID.NS

(([email protected];;))

Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - DEC-QUARTER CONSOL NET PROFIT 2.02 BILLION RUPEES

• STRIDES PHARMA SCIENCE LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.95 BILLION RUPEES

Further company coverage: SRID.NS

(([email protected];))

Oct 31 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• SEPT-QUARTER CONSOL NET PROFIT 1.28 BILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 12.21 BILLION RUPEES

Source text: [ID:]

Further company coverage: SRID.NS

(([email protected];;))

June 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT TO DIVEST 100% STAKE IN STRIDES CIS LIMITED

Source text: ID:nBSE8QfTWN

Further company coverage: SRID.NS

(([email protected];;))

** Shares of Strides Pharma Science SRID.NS rise 2.4% to 709 rupees

** Co's Q4 consolidated net profit jumps nearly five-fold Y/Y to 856.2 mln rupees ($10 mln), revenue rose ~14%

** SRID says it beat its forecast on all key metrics, including revenue, EBITDA

** Adds, growth led by US business growth, up 21.8% Y/Y and new launches

** Stock up ~5.5% YTD, eyes extending rally for a fourth session

($1 = 85.9340 Indian rupees)

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

March 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE - CO, ARCO LAB APPROVE DEMERGER OF IDENTIFIED BUSINESS OF ARCO LAB

Source text: ID:nNSEbkyWGB

Further company coverage: SRID.NS

(([email protected];))

March 14 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - UNIT PROPOSED TO ACQUIRE 100% STAKE IN AMEXEL PTE. LTD.

• STRIDES PHARMA SCIENCE LTD - UNIT PROPOSES TO CREATE BUSINESS PLATFORM IN SOUTHEAST ASIA

Source text: ID:nBSE5Grkf4

Further company coverage: SRID.NS

(([email protected];))

Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL NET PROFIT 879.5 MILLION RUPEES

• STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.54 BILLION RUPEES

Source text: ID:nBSE6pp5YM

Further company coverage: SRID.NS

(([email protected];))

Jan 20 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR ACETAMINOPHEN AND IBUPROFEN TABLETS

• STRIDES PHARMA SCIENCE LTD - APPROVAL WILL ENHANCE STRIDES' OTC PRODUCT PORTFOLIO

Source text: ID:nBSEbPMJqh

Further company coverage: SRID.NS

(([email protected];;))

Nov 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• RECEIPT OF NCLT APPROVAL FOR CREATION OF ONESOURCE

• FOLLOWING APPROVAL, ONESOURCE WILL ADVANCE TOWARDS LISTING ITS SHARES

Source text: ID:nNSE69gFWY

Further company coverage: SRID.NS

(([email protected];;))

Oct 25 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT SPG ACQUIRES REMAINING STAKE IN STRIDES SWITZERLAND FOR CHF 1.01 MILLION

Source text for Eikon: ID:nBSE3YQjWM

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS rise 2.5% to 1,599.5 rupees

** The pharma co posted a consolidated net profit of 932.3 mln rupees ($11 mln) vs a loss of 1.31 bln rupees a year ago

** Rev from ops rose 20% Y/Y

** More than 385,000 shares change hands, 1.1x its 30 day avg

** Stock has surged over two-fold so far this year

($1 = 84.0510 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Oct 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• ONESOURCE RECEIVES EQUITY COMMITMENTS OF 8.01 BILLION RUPEES

• COMMITMENTS FROM MARQUEE INVESTORS AT PRE-MONEY EQUITY VALUATION OF $1.65 BILLION

Source text for Eikon: ID:nBSE7MJ6X7

Further company coverage: SRID.NS

(([email protected];;))

Sept 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• RBI HAS LEVIED COMPOUNDING AMOUNT OF 15.1 MILLION RUPEES ON COMPANY

• ORDER IN MATTER OF GRANT OF STOCK OPTONS TO NONRESIDENT EMPLOYEE

Further company coverage: SRID.NS

(([email protected];))

Sept 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 60 MG

Source text for Eikon: ID:nBSEf6hKM

Further company coverage: SRID.NS

(([email protected];))

Sept 6 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - GETS USFDA APPROVAL FOR THEOPHYLLINE EXTENDED-RELEASE TABLET

Source text for Eikon: ID:nBSE3w42Yc

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma SRID.NS up 4% at record high of 1,020.75, highest since April 2017

** Co reported Q1 profit of 702 mln rupees vs 102.4 mln rupees year ago

** Stk up 57.4% YTD vs 28.4% gains in pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

May 22 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• RECEIVES USFDA APPROVAL FOR SUCRALFATE ORAL SUSPENSION, 1GM/10ML

• CO HAS SET TARGET TO LAUNCH ABOUT 60 NEW PRODUCTS OVER THREE YEARS IN US

Source text for Eikon: ID:nBSEkpNnl

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS are up around 2%

** SRID gets US FDA approval for Sevelamer Carbonate tablets, used to manage elevated phosphate levels in blood of patients with chronic kidney disease

** Stock is set to post its worst week since early Jan, down 4% for the week

** SRID up 31% YTD vs a 11% rise in Nifty Pharma Index .NIPHARM

(Reporting by Nishit Navin)

(([email protected];))

April 9 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 10 MG AND 20 MG

Source text for Eikon: ID:nBSE6GNL4V

Further company coverage: SRID.NS

(([email protected];))

March 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - PROPOSES TO CONSOLIDATE GROUP'S SOUTH AFRICAN BUSINESS UNDER TRINITY PHARMA (PROPRIETARY) LIMITED, SOUTH AFRICA

Source text for Eikon: ID:nBSE15mLyg

Further company coverage: SRID.NS

(([email protected];;))

March 28 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• CORPORATE INSOLVENCY RESOLUTION PROCESS AGAINST STRIDES ALATHUR STANDS STAYED BY APPELLATE TRIBUNAL

Source text for Eikon: ID:nBSE7qH1Gm

Further company coverage: SRID.NS

(([email protected];))

** Shares of Strides Pharma Science SRID.NS up 2.3%

** Stock roses as much as 4.8% to day's high of 834.6 rupees

** Pharmaceutical co's unit received U.S. FDA approval for Gabapentin Tablets USP, 600 mg and 800 mg

** It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain

** The product is bioequivalent to the reference-listed drug Neurontin Tablets, 600 mg and 800 mg, from Viatris Specialty LLC, co added

** The drug will be manufactured at Strides' Puducherry facility

** Stock is up 25.4% so far this year; after rising 85.6% in 2023

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

** Shares of Strides Pharma Science SRID.NS up 3.4%, easing from a jump of as much as 6.2% after Q3 results

** The pharma company reported a Q3 profit vs a year-ago loss, aided by high revenue from U.S. ops

** Stock has been trading above its 100-, 200- day simple moving average since April 2023

** Stock now up just over 8% YTD; its soared ~86% in 2023 after two years of losses

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Jan 11 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• UNIT ENTERED INTO A SHARE PURCHASE AGREEMENT FOR DIVESTMENT OF 100% SHAREHOLDING IN ERIS PHARMA GMBH, GERMANY

• DEAL FOR EURO 200,000

Source text for Eikon: ID:nBSE3vsMl7

Further company coverage: SRID.NS

(([email protected];))

Jan 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:

• STRIDES PHARMA SCIENCE LTD - UNIT ACQUIRED ADDITIONAL STAKE IN NEVITON SOFTECH

Source text for Eikon: ID:nBSEb0zDJ7

Further company coverage: SRID.NS

(([email protected];;))